Alerts will be sent to your verified email
Verify EmailAUROPHARMA
Aurobindo Pharma
|
Alkem Laboratories
|
Glenmark Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
861.0 . | 185.0 . | 13.0 . |
Number of ANDA's Approved By USFDA
|
719.0 . | 158.0 . | 25.0 . |
US DMF Filings
|
309.0 . | n/a | n/a |
Europe DMF Filings
|
2096.0 . | n/a | n/a |
R&D as a % of Total Sales
|
5.05 % | 5.0 % | 7.3 % |
Financials
|
|||
5 yr Average ROE
|
13.97 % | 17.38 % | 4.18 % |
5yr average Equity Multiplier
|
1.51 | 1.39 | 1.88 |
5yr Average Asset Turnover Ratio
|
0.71 | 0.86 | 0.79 |
5yr Avg Net Profit Margin
|
12.77 % | 14.54 % | 2.73 % |
Price to Book
|
1.92 | 4.88 | 6.59 |
P/E
|
17.99 | 27.03 | 55.71 |
5yr Avg Cash Conversion Cycle
|
-49.62 Days | -61.46 Days | -121.67 Days |
Inventory Days
|
59.48 Days | 56.11 Days | 40.44 Days |
Days Receivable
|
28.34 Days | 44.62 Days | 36.38 Days |
Days Payable
|
115.71 Days | 122.42 Days | 201.37 Days |
5yr Average Interest Coverage Ratio
|
43.78 | 24.48 | 3.48 |
5yr Avg ROCE
|
16.69 % | 22.76 % | 16.29 % |
5yr Avg Operating Profit Margin
|
19.28 % | 18.44 % | 15.62 % |
5 yr average Debt to Equity
|
0.21 | 0.18 | 0.49 |
5yr CAGR Net Profit
|
2.21 % | 6.44 % | n/a |
5yr Average Return on Assets
|
9.18 % | 12.47 % | 1.86 % |
Shareholdings
|
|||
Promoter Holding
|
51.82 % | 53.04 % | 46.65 % |
Share Pledged by Promoters
|
17.08 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -4.1 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
9.14 % | 8.82 % | 9.74 % |
Aurobindo Pharma
|
Alkem Laboratories
|
Glenmark Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|